SEC Form 424B3 filed by Kairos Pharma Ltd.
$KAPA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
10-Q - Kairos Pharma, LTD. (0001962011) (Filer)
8-K - Kairos Pharma, LTD. (0001962011) (Filer)
8-K - Kairos Pharma, LTD. (0001962011) (Filer)
Company makes important progress in 2025 and looks ahead into 2026 Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below. To our valued Kairos Pharma Shareholders, This year, Kairos has been focused on executing its Phase 2 randomized clinical trial of ENV105 in combination with apalutamide in patients with advanced metastatic prostate cancer. The study is designed to evaluate the safety, tolerability, and early signs of efficacy of ENV105, a CD105 antagonist, in men whose disease has progre
Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany. An interim efficacy analysis from the ongoing trial with ENV-105, a first-in-class CD105 antagonist, is being tested for safety and early efficacy in men with metastatic pr
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos's presentation, titled, "Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer" will take place in Berlin, Germany on October 17–21, 2025. Prostate cancer remains one of the most diagnosed cancers in men, with over a million new cases annually in the U.S. alone. Resistance to androgen-targeted therapies represents a major clinical challenge
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)